The management of metastatic prostate cancer

Turner, Bruce; Drudge-Coates, Lawrence

doi:10.1111/j.1749-771x.2009.01078.x

Cited by 4 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spinal cord compression is a clinical emergency requiring urgent management. The management of bone metastases in prostate cancer can include bisphosphonates or denosumab and radiation (Turner and Drudge‐Coates, ). Radioisotopes are associated with a reduction in pain and a subsequent improvement in quality of life (QoL) in some men (Turner et al ., ).…”

Section: The Physical Effects Of Mcrpc and Its Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Metastatic castrate‐resistant prostate cancer: a discussion of the physical and psychosocial effects

Flynn¹

2013

Int J of Uro Nursing

View full text Add to dashboard Cite

Management options for metastatic castrate-resistant prostate cancer (mCRPC) have increased in recent years resulting in more men living for longer with the disease. The implications for patients and health care services are considered through an examination of the literature in relation to the physical and psychosocial effects of mCRPC and its treatment, looking at quality of life (QoL) and service delivery implications. QoL in advanced prostate cancer has been well documented in the literature but studies involving those with mCRPC are sparse. There is a lack of evidence regarding psychological distress and effective psychological interventions for men with mCRPC. There is a need for research to understand the impact of new treatments on QoL of men and their partners, to establish effective psychological interventions for men with mCRPC and to quantify the increased demand for services with prolonged survival. The purpose of this discussion paper is to examine the physical and psychosocial effects of both disease and treatment, alongside QoL issues and consideration of the implications for service delivery. Khafegy et al. (2007) attempted to quantify complications for those in the final year of life with mCRPC. Their data showed patients experienced lower urinary

show abstract

Section: The Physical Effects Of Mcrpc and Its Treatmentmentioning

confidence: 99%

“…Turner and Drudge‐Coates () produced a thorough overview of the diagnosis and management of bone metastases and prostate cancer advocating nurses to take a proactive approach in the diagnosis and management of bone metastases to reduce the impact these complications have on patients.…”

Section: The Physical Effects Of Mcrpc and Its Treatmentmentioning

confidence: 99%

Metastatic castrate‐resistant prostate cancer: a discussion of the physical and psychosocial effects

Flynn¹

2013

Int J of Uro Nursing

View full text Add to dashboard Cite

show abstract

“…Nursing‐led initiatives in urological cancer care have placed many specialist nurses at the forefront of discussing, administering and reviewing treatments in patients with metastatic prostate cancer (Drudge‐Coates, 2005; Turner and Drudge‐Coates, 2009). Furthermore, many will be involved in renal monitoring and managing acute‐phase reactions because they may be most aware of changes in a patient's condition, adverse effects of treatment and changes in response to treatment.…”

Section: Implications For Nursing Practicementioning

confidence: 99%

Bone micro‐environment in prostate cancer: impact, treatment and implications for nursing practice

Drudge-Coates

Turner

2012

Int J of Uro Nursing

Self Cite

View full text Add to dashboard Cite

Prostate cancer is a substantial worldwide health care challenge. The disease is associated with detrimental effects on bone remodelling, mediated by the RANK/RANK ligand (RANKL) system. Androgen deprivation therapy (ADT) causes an imbalance in regular bone turnover, resulting in bone loss [cancer‐treatment‐induced bone loss (CTIBL)]. As prostate cancer progresses, bone metastases may develop, leading to a vicious cycle of increased bone turnover and tumour growth. In both cases, patients have reduced quality of life and an increased risk of fracture. However, data show that subcutaneous denosumab, a human monoclonal antibody that targets RANKL, is superior to the intravenous bisphosphonate zoledronic acid in delaying the onset of skeletal‐related events (SREs) and has a favourable safety profile in terms of nephrotoxicity and acute‐phase reactions. Urology nurse practitioners, as members of multidisciplinary teams, have an important role to play in assessing and helping to manage patients with bone‐related disease in prostate cancer. In this review, an overview of prostate‐cancer‐related bone disease is provided. Currently available pharmacological interventions for the different stages of the disease are discussed, and implications for urological nursing practice are suggested.

show abstract

“…and initiating prophylactic treatment where appropriate (Turner and Drudge-Coates, 2010). and initiating prophylactic treatment where appropriate (Turner and Drudge-Coates, 2010).…”

Section: What This Paper Addsmentioning

confidence: 99%

‘Nurse: My back hurts!’: case study review of Degarelix in metastatic prostate cancer

Turner

Drudge-Coates

Pati

2011

International Journal of Urological Nursing

Self Cite

View full text Add to dashboard Cite

In the management of metastatic prostate cancer, treatment with androgen deprivation therapy, initially with surgery via bilateral orchidectomy and more recently with medical therapy using gonadotropin‐releasing hormone (GnRH) agonists, has remained the key treatment approaches for this disease stage. Notably, patients express a preference towards a medical therapy approach. We present the case study of a patient with symptomatic metastatic prostate cancer treated with the new GnRH antagonist degarelix.

show abstract

The management of metastatic prostate cancer

Cited by 4 publications

References 53 publications

Metastatic castrate‐resistant prostate cancer: a discussion of the physical and psychosocial effects

Metastatic castrate‐resistant prostate cancer: a discussion of the physical and psychosocial effects

Bone micro‐environment in prostate cancer: impact, treatment and implications for nursing practice

‘Nurse: My back hurts!’: case study review of Degarelix in metastatic prostate cancer

Contact Info

Product

Resources

About